EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallbericht

Inappropriate secretion of fibroblast growth factor 23 despite hypophosphataemia with changes in bone turnover markers in a girl with systemic lupus erythematosus: Case report and review of the literature

Tadayasu Kawaguchi, Yasuji Inamo iD

Modern Rheumatology Case Reports · 2023

DOI: 10.1093/mrcr/rxac055 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Modern Rheumatology Case Reports, 2023. Verfasst von Tadayasu Kawaguchi und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Pediatrics, Nihon University School of Medicine, Itabashi Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Hypophosphatemia, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report an 11-year-old girl with systemic lupus erythematosus (SLE) who showed hypophosphataemia (1.7 mg/dl, normal range: 3.9–5.8 mg/dl), a decrease in the tubular maximum reabsorption of phosphate/glomerular filtration rate (TmP/GFR) (0.77 mg/dl, normal range: 3.4–5.6 mg/dl), and an elevated serum fibroblast growth factor 23 (FGF23) (circulating phosphate-regulatory hormone) concentration (FGF23: 282 pg/ml, normal range: <52 pg/ml) at the onset. The patient was treated with intravenous pulse methylprednisolone, oral prednisolone, mycophenolate mofetil, hydroxychloroquine, and phosphorus supplement. Serum FGF23 concentrations decreased to near the reference value at 5 months after the onset of SLE, and the TmP/GFR (4.61 mg/dl) simultaneously improved. The urinary deoxypyridinoline (bone resorption marker) concentration on admission (18.9 nmol/mmol creatinine, normal range: 75.4 ± 6.8 nmol/mmol creatinine) was greatly reduced, and the bone-type alkaline phosphatase (bone formation marker) concentration (30.6 µg/l, normal range: 58.6 ± 15.3 µg/l) was also reduced during the increase in FGF23 concentrations before steroid therapy was initiated. The reason for the inappropriate secretion of FGF23, despite hypophosphataemia, remains unknown. The findings in our case suggest that changes in bone turnover markers can occur in patients with SLE and excess inappropriate secretion of FGF23, despite severe and persistent hypophosphataemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypophosphatemiaLupus Erythematosus, SystemicFemaleHumansChildFibroblast Growth Factor-23CreatinineFibroblast Growth FactorsPhosphatesBone Remodeling

Stichwörter der Autor:innen

Fibroblast growth factor 23bone turnover markerhypophosphataemialupus nephritissystemic lupus erythematosus

Substanzen

Fibroblast Growth Factor-23CreatinineFibroblast Growth FactorsPhosphates

Autor:innen und Institutionen

  • The Department of Pediatrics, Nihon University School of Medicine, Itabashi Hospital, Tokyo, Japan.
  • Center for Child and Adolescent Health, Pediatric Rheumatology, and Endocrinology, Jiai Hospital, Tokyo, Japan.
  • Faculty of Medical Sciences, Teikyo University of Science, Tokyo, Japan.

ORCID-Profile: Yasuji Inamo

Zitieren

APA

Kawaguchi, T., & Inamo, Y. (2023). Inappropriate secretion of fibroblast growth factor 23 despite hypophosphataemia with changes in bone turnover markers in a girl with systemic lupus erythematosus: Case report and review of the literature. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxac055

Vancouver

Kawaguchi T, Inamo Y. Inappropriate secretion of fibroblast growth factor 23 despite hypophosphataemia with changes in bone turnover markers in a girl with systemic lupus erythematosus: Case report and review of the literature. Modern Rheumatology Case Reports. 2023. doi:10.1093/mrcr/rxac055

BibTeX
@article{Kawaguchi2023,
  author = {Kawaguchi, Tadayasu and Inamo, Yasuji},
  title = {Inappropriate secretion of fibroblast growth factor 23 despite hypophosphataemia with changes in bone turnover markers in a girl with systemic lupus erythematosus: Case report and review of the literature},
  journal = {Modern Rheumatology Case Reports},
  year = {2023},
  doi = {10.1093/mrcr/rxac055}
}
Kostenlos starten →